• CG Oncology highlighted Phase 3 BOND-003 Cohort C in high-risk BCG-unresponsive CIS, reporting 76% complete response at any time.
• Durability metrics showed 46.4% complete response at 12 months, 41.8% at 24 months, with 90% of 12-month responders remaining in response.
• Safety update cited zero grade 3+ treatment-related adverse events or deaths, with most adverse events grade 1-2.
• Phase 3 BOND-003 Cohort P in high-risk BCG-unresponsive Ta/T1 reported high-grade event-free survival of 95.7% at 3 months, 84.6% at 6 months.
• Manufacturing readiness noted current capacity of 40,000-50,000 vials per year, with a 10x scale-up process underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.